Structural annotation and elucidation of conjugated phenolic compounds in black, green, and white tea extracts
Justin J.J. van der Hooft M. Akermi F. Yelda Ünlü V. Mihaleva V. Gomez Roldan R.J. Bino Ric de Vos Jacques Vervoort
Justin van der Hooft
van der Hooft Justin / Justin J.J. van der Hooft
ORCID: 0000-0002-9340-5511
Structural elucidation of low abundant metabolites in complex sample matrices 10.1007/s11306-013-0519-8
Non-smoky GLYCOSYLTRANSFERASE1 prevents the release of smoky aroma from tomato fruit 10.1105/tpc.113.114231
Automatic chemical structure annotation of an LC-MSn based metabolic profile from green tea 10.1021/ac400861a
Substructure-based annotation of high-resolution multistage MSn spectral trees 10.1002/rcm.6364
Structural annotation and elucidation of conjugated phenolic compounds in black, green, and white tea extracts 10.1021/jf300297y
Structural elucidation and quantification of phenolic conjugates present in human urine after tea intake 10.1021/ac3017339
Spectral trees as a robust annotation tool in LC-MS based metabolomics 10.1007/s11306-011-0363-7
Metabolite identification using automated comparison of high-resolution multistage mass spectral trees 10.1021/ac2034216
Inhibitory activity of plumbagin produced by Drosera intermedia on food spoilage fungi 10.1002/jsfa.5522
A strategy for fast structural elucidation of metabolites in small volume plant extracts using automated MS-guided LC-MS-SPE-NMR 10.1002/mrc.2833
Thermal diffusivity of periderm from tomatoes of different maturity stages as determined by the concept of the frequency-domain open photoacoustic cell 10.1063/1.3530735
Polyphenol identification based on systematic and robust high-resolution accurate mass spectrometry fragmentation 10.1021/ac102546x
Iridoid and caffeoyl phenylethanoid glycosides of the endangered carnivorous plant Pinguicula lusitanica L. (Lentibulariaceae) 10.1016/j.bse.2009.05.003
Topic modeling for untargeted substructure exploration in metabolomics 10.1073/pnas.1608041113
Propagating annotations of molecular networks using in silico fragmentation 10.1371/journal.pcbi.1006089
Did a plant-herbivore arms race drive chemical diversity in Euphorbia? 10.1101/323014
Automatic Compound Annotation from Mass Spectrometry Data Using MAGMa. 10.5702/massspectrometry.S0033
Interactions of blacktea polyphenols with human gut microbiota: implications for gut and cardiovascular health 10.3945/ajcn.113.058263
Identification of a drimenol synthase and drimenol oxidase from Persicaria hydropiper, involved in the biosynthesis of insect deterrent drimanes 10.1111/tpj.13527
Enhanced Acylcarnitine Annotation in High-Resolution Mass Spectrometry Data: Fragmentation Analysis for the Classification and Annotation of Acylcarnitines 10.3389/fbioe.2015.00026
Rapid and sustained systemic circulation of conjugated gut microbiol catabolites after single-dose black tea extract consumption 10.1021/pr5001253
In Silico Prediction and Automatic LC–MSn Annotation of Green Tea Metabolites in Urine 10.1021/ac403875b
Unexpected differential metabolic responses of Campylobacter jejuni to the abundant presence of glutamate and fucose 10.1007/s11306-018-1438-5
Comprehensive mass spectrometry-guided plant specialized metabolite phenotyping reveals metabolic diversity in the cosmopolitan plant family Rhamnaceae 10.1101/463620
Deciphering complex metabolite mixtures by unsupervised and supervised substructure discovery and semi-automated annotation from MS/MS spectra 10.1101/491506
Accelerating metabolite identification in natural product research: toward an ideal combination of LC-HRMS/MS and NMR profiling, in silico databases and chemometrics 10.1021/acs.analchem.8b05112
Untargeted Mass Spectrometry-Based Metabolomics Tracks Molecular Changes in Raw and Processed Foods and Beverages 10.1101/347716
Absorption, metabolism, distribution and excretion of (−)-epicatechin: A review of recent findings
Metabolite Identification in Complex Mixtures Using Nuclear Magnetic Resonance Spectroscopy 10.1007/978-3-319-28275-6_6-2 web-based topic modelling for substructure discovery in mass spectrometry 10.1093/bioinformatics/btx582
A comprehensive evaluation of the [2-14C](–)-epicatechin metabolome in rats
The food metabolome: a window over dietary exposure 10.3945/ajcn.113.076133
Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols 10.3945/ajcn.113.058958
Unsupervised Discovery and Comparison of Structural Families Across Multiple Samples in Untargeted Metabolomics 10.1021/acs.analchem.7b01391
A community-driven paired data platform to accelerate natural product mining by combining structural information from genomes and metabolomes 10.18174/FAIRdata2018.16286
Implementations of the chemical structural and compositional similarity metric in R and Python 10.1101/546150
Comprehensive mass spectrometry-guided phenotyping of plant specialized metabolites reveals metabolic diversity in the cosmopolitan plant family Rhamnaceae 10.1111/tpj.14292
A genetical metabolomics approach for bioprospecting plant biosynthetic gene clusters 10.1186/s13104-019-4222-3
The Metabolomics Society—Current State of the Membership and Future Directions 10.3390/metabo9050089
Deciphering complex metabolite mixtures by unsupervised and supervised substructure discovery and semi-automated annotation from MS/MS spectra 10.1039/C8FD00235E
MolNetEnhancer: enhanced molecular networks by integrating metabolome mining and annotation tools 10.1101/654459
Substantial extracellular metabolic differences found between phylogenetically closely related probiotic and pathogenic strains of Escherichia coli 10.3389/fmicb.2019.00252
Assessing specialized metabolite diversity in the cosmopolitan plant genus Euphorbia l. 10.3389/fpls.2019.00846
Molnetenhancer: Enhanced molecular networks by integrating metabolome mining and annotation tools 10.3390/metabo9070144
In Silico Optimization of Mass Spectrometry Fragmentation Strategies in Metabolomics 10.3390/metabo9100219
MIBiG 2.0: a repository for biosynthetic gene clusters of known function 10.1093/nar/gkz882
Untargeted mass spectrometry-based metabolomics approach unveils molecular changes in raw and processed foods and beverages 10.1016/j.foodchem.2019.125290
The Natural Products Atlas: An Open Access Knowledge Base for Microbial Natural Products Discovery 10.1021/acscentsci.9b00806
Mass spectrometry searches using MASST 10.1038/s41587-019-0375-9
Assessing specialized metabolite diversity of Alnus species by a digitized LC–MS/MS data analysis workflow 10.1016/j.phytochem.2020.112292
Microbiome-derived carnitine mimics as previously unknown mediators of gut-brain axis communication 10.1126/sciadv.aax6328
Chemically-informed Analyses of Metabolomics Mass Spectrometry Data with Qemistree 10.1101/2020.05.04.077636
Linking genomics and metabolomics to chart specialized metabolic diversity 10.1039/D0CS00162G
Reproducible molecular networking of untargeted mass spectrometry data using GNPS 10.1038/s41596-020-0317-5
Decomposing metabolite set activity levels with PALS 10.1101/2020.06.07.138974
Ranking microbial metabolomic and genomic links in the NPLinker framework using complementary scoring functions 10.1101/2020.06.12.148205
Phenylpropane as an Alternative Dearomatizing Unit of Indoles: Discovery of Inaequalisines A and B Using Substructure-Informed Molecular Networking 10.1021/acs.orglett.0c02153
matchms - processing and similarity evaluation of mass spectrometry data 10.1101/2020.08.06.239244
Spec2Vec: Improved mass spectral similarity scoring through learning of structural relationships 10.1101/2020.08.11.245928
BiG-SLiCE: A Highly Scalable Tool Maps the Diversity of 1.2 Million Biosynthetic Gene Clusters 10.1101/2020.08.17.240838
matchms - processing and similarity evaluation of mass spectrometry data. 10.21105/joss.02411
ReDU: a framework to find and reanalyze public mass spectrometry data 10.1038/s41592-020-0916-7
Feature-based molecular networking in the GNPS analysis environment 10.1038/s41592-020-0933-6
Rapid Development of Improved Data-dependent Acquisition Strategies 10.1101/2020.09.11.293092
Chemically informed analyses of metabolomics mass spectrometry data with Qemistree 10.1038/s41589-020-00677-3
Auto-deconvolution and molecular networking of gas chromatography–mass spectrometry data 10.1038/s41587-020-0700-3
The ant fungus garden acts as an external digestive system 10.1101/2020.11.18.389361
BiG-MAP: an automated pipeline to profile metabolic gene cluster abundance and expression in microbiomes 10.1101/2020.12.14.422671
BiG-SLiCE: A highly scalable tool maps the diversity of 1.2 million biosynthetic gene clusters 10.1093/gigascience/giaa154
Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs 10.1371/journal.ppat.1008932
Comparative Metabologenomics Analysis of Polar Actinomycetes 10.3390/md19020103
Ranking Metabolite Sets by Their Activity Levels 10.3390/metabo11020103
Spec2Vec: Improved mass spectral similarity scoring through learning of structural relationships 10.1371/journal.pcbi.1008724
Rapid Development of Improved Data-Dependent Acquisition Strategies 10.1021/acs.analchem.0c03895
MS2DeepScore - a novel deep learning similarity measure for mass fragmentation spectrum comparisons 10.1101/2021.04.18.440324
Ranking microbial metabolomic and genomic links in the NPLinker framework using complementary scoring functions 10.1371/journal.pcbi.1008920
Metabolomics-Guided Elucidation of Plant Abiotic Stress Responses in the 4IR Era: An Overview 10.3390/metabo11070445
Chemical Gradients of Plant Substrates in an Atta texana Fungus Garden 10.1128/mSystems.00601-21
Comprehensive Large-Scale Integrative Analysis of Omics Data To Accelerate Specialized Metabolite Discovery 10.1128/mSystems.00726-21
Vanessa Roldan
Roldan Vanessa / Vanessa Roldan-Schilling
ORCID: 0000-0002-4945-6602
Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. 10.1160/th16-12-0961
Predicting bleeding risk after coronary surgery: Let's focus on modifiable risk factors and simple, practical decision making. 10.1160/th17-02-0131
Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. 10.1038/srep43500
Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? 10.1038/srep41565
Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation. 10.1016/j.rec.2016.11.032
Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. 10.1016/j.rec.2016.11.006
Applicability of the modified CHA2DS2-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. 10.1016/j.ejim.2016.11.006
Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. 10.1177/1099800416671211
Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients? 10.1253/circj.cj-16-0471
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. 10.1007/s40119-016-0066-2
Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention. 10.1160/th16-07-0512
Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect. 10.1111/jth.13372
The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. 10.1016/j.ijcard.2016.04.167
MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. 10.1371/journal.pone.0154751
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk. 10.1093/cvr/cvw049
Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. 10.1253/circj.cj-15-0992
Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. 10.1093/europace/euv354
The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. 10.1586/14779072.2016.1116941
Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. 10.1160/th14-09-0814
Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. 10.1016/j.rec.2015.06.021
A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event. 10.1016/j.thromres.2015.06.039
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). 10.1093/europace/euv190
sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. 10.1111/eci.12482
The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study. 10.1016/j.amjmed.2015.05.036
Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. 10.1186/s12959-015-0046-0
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. 10.1371/journal.pone.0124719
The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. 10.1160/th14-12-1087
Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. 10.5551/jat.26161
Biomarkers: GDF-15 and risk stratification in atrial fibrillation. 10.1038/nrcardio.2014.190
Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. 10.1016/j.rec.2014.06.026
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. 10.1160/th14-01-0092
SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. 10.1016/j.amjmed.2014.05.023
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. 10.2217/pgs.13.232
Common Questions in Anticoagulation Management in Atrial Fibrillation. 10.1016/j.ccep.2013.10.005
Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. 10.1161/strokeaha.113.003338
Biomarkers in atrial fibrillation: an overview. 10.1111/ijcp.12304
β-Trace protein and prognosis in patients with atrial fibrillation receiving anticoagulation treatment. 10.1378/chest.13-0922
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. 10.1160/th13-07-0556
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. 10.1016/j.jacc.2013.08.1623
Novel oral anticoagulants in cardiovascular disease. 10.1177/1074248413501392
Conventional and new oral anticoagulants in the treatment of chest disease and its complications. 10.1164/rccm.201301-0141pp
Novel associations of VKORC1 variants with higher acenocoumarol requirements. 10.1371/journal.pone.0064469
Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? 10.1160/th13-01-0054
Association of the thrombomodulin gene c.1418C>T polymorphism with thrombomodulin levels and with venous thrombosis risk. 10.1161/atvbaha.113.301360
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). 10.1016/j.amjcard.2012.12.045
A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. 10.1378/chest.12-0964
Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. 10.1378/chest.12-0608
The prognostic role of the adiponectin levels in atrial fibrillation. 10.1111/eci.12028
Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. 10.3109/07853890.2012.732702
Creating a genotype-based dosing algorithm for acenocoumarol steady dose. 10.1160/th12-08-0631
Comparative determination and monitoring of biomarkers of necrosis and myocardial remodeling between radiofrequency ablation and cryoablation. 10.1111/pace.12017
Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. 10.1111/eci.12004
Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. 10.1093/ageing/afs121
Pro: "Antidote for new anticoagulants"--specific target of inhibition requires a specific target for neutralisation. 10.1160/th12-06-0440
High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. 10.1111/j.1538-7836.2012.04812.x
Edoxaban in Japanese patients with nonvalvular atrial fibrillation: not the same dose for everybody. 10.1253/circj.cj-12-0765
Subclinical atherosclerotic endothelial damage as predictor for bleeding in anticoagulated atrial fibrillation patients. 10.1111/j.1365-2796.2012.02565.x
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? 10.1161/circinterventions.112.968792
[Should we add antiplatelet therapy to oral anticoagulation in patients with atrial fibrillation and vascular disease? Review of available evidence]. 10.1016/j.acmx.2012.03.002
Oral anticoagulation in chronic kidney disease: A huge challenge. 10.1160/th12-05-0324
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. 10.1016/j.rec.2012.02.016
Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? 10.1517/14656566.2012.688954
Structural annotation and elucidation of conjugated phenolic compounds in black, green, and white tea extracts. 10.1021/jf300297y
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. 10.1161/circep.111.967000
miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle. 10.2119/molmed.2012.00062
Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism. 10.1160/th11-06-0423
Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. 10.1111/j.1538-7836.2011.04451.x
Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage? 10.1016/j.thromres.2011.07.005
Prognostic value of mean platelet volume in patients with non-ST-elevation acute coronary syndrome. 10.1177/0003319711413892
Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study. 10.1016/j.thromres.2011.05.022
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. 10.1016/j.jacc.2010.12.033
Peri-operative management of ophthalmic patients taking antithrombotic therapy. 10.1111/j.1742-1241.2010.02538.x
Influence of the F12 -4 C>T polymorphism on hemostatic tests. 10.1097/mbc.0b013e32833a9048
An evaluation of the CHADS₂ stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. 10.1378/chest.10-1408
CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. 10.3109/07853890.2010.499131
Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. 10.3109/07853890.2010.507601
Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. 10.1016/j.thromres.2010.06.019
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. 10.1160/th10-01-0022
Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. 10.1007/s00277-010-1000-7
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. 10.3324/haematol.2010.023432
Hypouricemic effect of statins: another pleiotropic benefit? 10.1016/j.jtcvs.2009.08.063
Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. 10.1111/j.1538-7836.2010.03800.x
The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage? 10.1136/hrt.2009.182105
Measuring the prognostic impact of ferritin levels in myelodysplastic syndrome patients: the role of susceptibility biases. 10.1038/leu.2009.229
Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. 10.1111/j.1742-1241.2009.02127.x
Pharmacogenetics in cardiovascular antithrombotic therapy. 10.1016/j.jacc.2009.04.084
Implications of pharmacogenetics for oral anticoagulants metabolism. 10.2174/138920009789375432
The prognostic value of biomarkers after a premature myocardial infarction. 10.1016/j.ijcard.2009.02.019
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. 10.1182/blood-2008-09-176222
Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. 10.1093/eurheartj/ehp045
Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. 10.1093/eurheartj/ehn538
Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. 10.1080/07853890903111000
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. 10.1016/j.thromres.2008.11.003
Endothelial protein C receptor polymorphisms and risk of myocardial infarction. 10.3324/haematol.13066
The impact of statin use on atrial fibrillation. 10.1093/qjmed/hcn101
Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease. 10.1016/j.ijcard.2008.06.076
Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. 10.1016/j.ijcard.2008.04.020
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. 10.1016/j.ahj.2008.01.035
Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. 10.1016/j.cardfail.2008.02.006
JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. 10.1007/s00277-008-0474-z
Letter by Roldán et al regarding article, "Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass". 10.1161/circulationaha.107.746461
Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk. 10.1080/07853890802108412
Gamma-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. 10.1016/j.thromres.2007.12.007
Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. 10.1016/j.ijcard.2007.11.044
A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. 10.1111/j.1365-2796.2007.01871.x
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. 10.1093/eurheartj/ehm488
Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. 10.1111/j.1365-2796.2007.01823.x
Common carotid artery intima-media thickness and intracranial pulsatility index in non-ST-elevation acute coronary syndromes. 10.1159/000106979
The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. 10.1111/j.1538-7836.2007.02630.x
Premature myocardial infarction: clinical profile and angiographic findings. 10.1016/j.ijcard.2007.02.038
The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. 10.3324/haematol.10689
Prognostic value of annexin A5 -1 C/T polymorphism in a long term follow-up after premature myocardial infarction. 10.1111/j.1538-7836.2007.02419.x
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. 10.1182/blood-2006-08-040774
Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. 10.1016/j.amjcard.2006.07.019
Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers? 10.1007/s11239-006-4384-4
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. 10.1182/blood-2005-08-3249
Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. 10.2217/14796678.2.2.197
Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task. 10.1016/j.ijcard.2005.09.034
Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. 10.1160/th05-06-0453
Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in atrial fibrillation? 10.1016/j.ijcard.2005.08.057
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. 10.1016/j.amjcard.2005.07.124
Pharmacogenetics in cardiovascular antithrombotic therapy. 10.2174/156801605774322346
[Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease]. 10.1157/13078130
Are there ethnic differences in the circadian variation in onset of acute myocardial infarction? A comparison of 3 ethnic groups in Birmingham, UK and Alicante, Spain. 10.1016/j.ijcard.2004.12.002
Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. 10.1016/j.amjcard.2004.12.016
Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. 10.1016/j.thromres.2005.01.005
Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people. 10.1016/j.ijcard.2003.11.025
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. 10.1016/j.jacc.2004.09.051
Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol. 10.1111/j.1538-7836.2004.01027.x
Genetic polymorphisms and thromoembolic risk in atrial fibrillation. 10.1007/s11239-004-0211-y
Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. 10.1016/j.ahj.2004.04.020
Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: effects of antihypertensive agents on fibrinolytic function. 10.1038/sj.jhh.1001754
Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. 10.1016/j.yjmcc.2004.06.001
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. 10.1136/hrt.2003.024521
Soluble E-selectin, interleukin-6 and tissue factor in two cases of meningococcal septicaemia. 10.1097/00001721-200403000-00009
Kinetics and mechanism of the reduction of CrVI and CrV by D-lactobionic acid. 10.1016/j.jinorgbio.2003.11.005
Matrix metalloproteinases in atrial fibrillation. 10.1016/j.jacc.2003.10.019
Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. 10.1016/s0195-668x(03)00239-2
Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. 10.1016/s0002-9149(03)00274-1
Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? 10.1161/01.str.0000065431.76788.d9
Diurnal variation of international normalised ratio in patients under oral anticoagulation. 10.1016/s0049-3848(03)00108-7
Fibrinolytic function and atrial fibrillation. 10.1016/s0049-3848(03)00259-7
[Annexin V levels in survivors of early myocardial infarction]. 10.1016/s0300-8932(02)76794-8
[Factor XIII Val34Leu polymorphism and premature myocardial infarction]. 10.1016/s0300-8932(02)76767-5
[Hemolytic anemia secondary to paravalvular regurgitation]. 10.1016/s0300-8932(02)76737-7
Prothrombin fragment F1+2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples. 10.1016/s0167-5273(02)00063-3
Do protein Z levels influence the prothrombotic state in atrial fibrillation? 10.1016/s0049-3848(02)00142-1
The role of tissue plasminogen activator on the progression of the coronary disease. 10.1053/euhj.2001.2633
[Severe hypercalcaemia as initial manifestation of B-cell non-Hodgkin's lymphoma] 10.1016/s0025-7753(01)72017-9
Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction. 10.1016/s0167-5273(00)00471-x
Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. 10.1016/s0002-9149(99)00453-1
Hypofibrinolysis in atrial fibrillation. 10.1016/s0002-8703(98)70149-8
Development of the human submandibular salivary gland. 10.1177/00220345930720081101
Developmental differences in the ossification process of the human corpus and ramus mandibulae. 10.1002/ar.1092350216
[Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants]. 10.1016/s0025-7753(12)70035-0
[Can we expect polymorphisms to answer our questions?]. 10.1016/s0300-8932(04)77251-6
[Pure red cell aplasia and myelodysplastic changes]. 10.1016/s0014-2565(02)71022-9
[Thrombogenic and endothelial damage markers in patients with ischemic systolic impairment] 10.1016/s0300-8932(01)76473-1
[Improvement in fibrinolytic function following anticoagulant treatment in chronic rheumatic atrial fibrillation] 10.1016/s0300-8932(99)74861-x
Strategies for prediction and early detection of atrial fibrillation: present and future. 10.1093/europace/euw131
Non-Vitamin K antagonist Oral Anticoagulants: Impact of Non-adherence and Discontinuation. 10.1080/14740338.2017.1351542
Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. 10.1038/s41598-017-11683-2
Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers. 10.1080/07853890.2017.1378429
Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. 10.1160/th17-07-0478
Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores. 10.1161/jaha.117.006490
Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. 10.1093/europace/eux314
Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. 10.1111/joim.12702
High incidence of FXI deficiency in a Spanish town caused by 11 different mutations and the first duplication of F11: Results from the Yecla study. 10.1111/hae.13356
Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. 10.1016/j.amjcard.2017.09.003
Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. 10.1111/ijcp.13069
MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. 10.1161/atvbaha.117.310597
Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. 10.1160/th17-06-0416
Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis. 10.1007/s10549-017-4656-z
Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency. 10.1016/j.thromres.2017.12.023
Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. 10.1016/j.clinthera.2017.11.014
Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in 'real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. 10.1016/j.ijcard.2017.11.087
Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. 10.1160/th17-10-0710
Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED. 10.1016/j.ahj.2017.11.004
Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. 10.1111/eci.12929
Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. 10.1007/s11606-017-4279-4
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. 10.1093/europace/euy054
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. 10.1093/eurheartj/ehy136
Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. 10.1253/circj.cj-17-1318
Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. 10.5603/cj.2018.0014
Oral anticoagulation and comorbidities; too many details for clinical practice? 10.1016/j.ijcard.2018.03.115
miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. 10.1371/journal.pone.0198932
Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. 10.1016/j.rec.2018.01.029
Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. 10.1016/j.amjcard.2018.05.012
A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. 10.1016/j.mayocp.2018.01.028
Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. 10.1055/s-0038-1641737
Efficacy and Safety of Peri-procedural Bridging Therapy with Low Molecular Weight Heparin in Atrial Fibrillation Patients under Vitamin K Antagonists. 10.1093/qjmed/hcy250
Increasing Therapy Related Myeloid Neoplasms in Multiple Myeloma. 10.1111/eci.13050
The effect of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single patient data meta-analysis in more than 15,000 individuals. 10.1002/cpt.1323
The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. 10.1055/s-0039-1696955
Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. 10.1055/s-0039-1692440
Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. 10.1161/strokeaha.118.024305
Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation 10.1136/bmjopen-2019-033712
Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project 10.1055/s-0040-1712914
ALG12‐CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant 10.1002/mgg3.1304
Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy 10.1080/14656566.2020.1789099
Influence of the matrix type over the concentration of GDF-15 10.1136/jim-2020-001351
Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation 10.1016/j.mayocp.2020.05.046
Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation 10.3390/jcm9113645
Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-World vs. Clinical Trial Evidence. 10.1111/bcp.14961
Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. 10.3390/jcm10040715
Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. 10.1007/s11239-021-02407-5
Factor XI, much more than an innocent observer. 10.1111/jth.15093
Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs 'real-world'. 10.1111/ijcp.13888
Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. 10.1186/s13023-020-01564-9